---
provider: claude_code
model: claude-haiku-4-5-20251001, claude-sonnet-5
cached: false
start_time: '2026-08-18T05:06:12.153170'
end_time: '2026-08-18T05:11:14.328945'
duration_seconds: 302.18
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Dilated Cardiomyopathy 1A
  mondo_id: ''
  category: Genetic
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-4-5-20251001
  - claude-sonnet-5
  web_search_requests: 21
  num_turns: 24
  total_cost_usd: 2.1651932000000005
  session_id: 6054099f-a91d-526b-85b2-1397367e9a3a
  stop_reason: end_turn
  assistant_text_blocks: 3
citation_count: 41
reference_validation:
  total_references: 37
  verified: 36
  not_found: 0
  unverifiable: 1
  confabulation_rate: 0.0
  quotes_checked: 2
  quotes_valid: 1
  quotes_unsupported: 1
  unsupported_quote_references:
  - PMID:10580070
  quotes_not_checkable: 1
  relevance_assessed: 36
  on_topic: 24
  needs_review: true
  validator_version: 0.2.1
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Dilated Cardiomyopathy 1A
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on **Dilated Cardiomyopathy 1A** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

I'll research Dilated Cardiomyopathy 1A (DCM1A, LMNA-related dilated cardiomyopathy) using web search and fetch tools, then compile the comprehensive report.

I have comprehensive data now. Let me compile the full research report.

I now have sufficient depth to compile the comprehensive report.

# Dilated Cardiomyopathy 1A (LMNA-Related Dilated Cardiomyopathy): Comprehensive Research Report

## 1. Disease Information

**Overview:** Dilated Cardiomyopathy 1A (CMD1A/DCM1A) is an autosomal dominant, monogenic laminopathy caused by heterozygous pathogenic variants in *LMNA* (lamin A/C), the gene encoding the major structural proteins of the nuclear lamina. The disease is defined by left ventricular (LV) enlargement and/or reduced systolic function that is characteristically preceded by, or co-occurs with, significant cardiac conduction system disease and/or atrial and ventricular arrhythmias — a combination that distinguishes it from most other genetic DCMs (GeneReviews, PMID:20301717, https://www.ncbi.nlm.nih.gov/books/NBK1674/). Disease onset is typically in early-to-mid adulthood (third–fourth decade), though presentation ranges from incidental ECG findings in asymptomatic gene carriers to sudden cardiac death (SCD) as the first manifestation, sometimes with minimal or no structural disease.

**Key identifiers:**
- **OMIM:** #115200 — CARDIOMYOPATHY, DILATED, 1A; CMD1A (https://omim.org/entry/115200)
- **Gene/locus:** *LMNA*, chromosome 1q22 (OMIM gene *150330)
- **MONDO:** MONDO:0007269
- **Orphanet:** ORPHA:300751 — "Familial dilated cardiomyopathy with conduction defect due to LMNA mutation" (https://www.orpha.net/en/disease/detail/300751); see also Orphanet's gene page (https://www.orpha.net/en/disease/gene/LMNA)
- **ICD-10:** I42.0 (Dilated cardiomyopathy)
- **HGNC:** LMNA, HGNC:6636
- **Related allelic OMIM entries:** Emery-Dreifuss muscular dystrophy 2 (AD), #181350; limb-girdle muscular dystrophy 1B; familial partial lipodystrophy 2 (Dunnigan type), #151660; Charcot-Marie-Tooth disease type 2B1, #605588; Hutchinson-Gilford progeria syndrome, #176670; mandibuloacral dysplasia; heart-hand syndrome, Slovenian type, #610140

**Synonyms:** LMNA-related dilated cardiomyopathy; LMNA cardiomyopathy; familial dilated cardiomyopathy with conduction system disease; cardiac laminopathy; lamin A/C cardiomyopathy.

**Evidence basis:** The dismech-relevant literature is predominantly aggregated, cohort-level, and family-pedigree data from human clinical genetics (multicenter European/US cardiogenetics cohorts, e.g., van Rijsingen et al. 2012 [PMID:22281253], Captur et al. 2018 [PMID published in *Eur Heart J*, DOI 10.1093/eurheartj/ehx808]), supplemented by mechanistic data from iPSC-cardiomyocyte and mouse/zebrafish models rather than individual-EHR-level data.

---

## 2. Etiology

### Disease Causal Factors
CMD1A is caused **exclusively by heterozygous, typically dominant-negative or haploinsufficient, pathogenic variants in *LMNA***. This is a purely genetic/monogenic etiology — there is no known infectious or primary environmental cause of the disease itself (environmental/lifestyle factors act only as modifiers of penetrance/progression, see below). The founding description was Fatkin et al., *N Engl J Med* 1999 (PMID:10580070), which mapped autosomal dominant DCM with conduction-system disease to chromosome 1p1–q21 and identified missense mutations in the *LMNA* rod domain.

> "Missense mutations in the rod domain of the lamin A/C gene provide a genetic cause for dilated cardiomyopathy and conduction-system disease... this intermediate filament protein has an important role in cardiac conduction and contractility." (Fatkin et al. 1999, *NEJM* 341:1715-1724, PMID:10580070)

### Genetic Risk Factors
- **Causal variant class:** More than 450 disease-associated *LMNA* variants have been reported across the ~15 recognized laminopathy phenotypes; cardiac disease results from missense, nonsense, frameshift/indel, and splice-site variants distributed across the gene, with no single dominant hotspot (PMC6335092, "Mechanisms of allelic and clinical heterogeneity of lamin A/C phenotypes").
- **Variant-class risk stratification (a documented genotype–phenotype gradient, not a strict correlation):**
  - Non-missense variants (truncating/frameshift/indel, and splice-site variants) confer higher risk of malignant ventricular arrhythmia (MVA) and conduction disease before age 50–60 than missense variants (van Rijsingen et al. 2012, PMID:22281253; GeneReviews PMID:20301717).
  - Splice-site variants specifically correlate with increased SCD risk.
- **Modifier/digenic risk:** Co-occurring rare *TTN* (titin) truncating variants act as genetic modifiers that substantially worsen disease severity in *LMNA* carriers — "doubly heterozygous" *LMNA*/*TTN* patients required heart transplantation at a significantly younger age than *LMNA*-only carriers, with myocardial specimens showing increased nuclear length, sarcomeric disorganization, and myonuclear clustering (Roncarati et al. 2013, *Eur J Hum Genet*, PMID:23463027).
- **A TMPO (LAP2) missense polymorphism (p.Arg690Cys)** has been reported to modify leukocyte nuclear morphology abnormalities in a family with an *LMNA* truncating variant (PMC9656322), consistent with a broader modifier-gene concept in laminopathies.
- **Family history:** The strongest and most actionable "risk factor" is a first-degree relative with a known pathogenic *LMNA* variant; autosomal dominant inheritance confers 50% transmission risk per offspring.

### Environmental/Non-genetic Risk Factors
- No established environmental, toxic, occupational, or infectious risk factor for CMD1A specifically has strong human evidence; the disease is fully genetically determined once a pathogenic variant is present. General DCM risk modifiers (alcohol, viral myocarditis, tachycardia-mediated stress) may plausibly accelerate decompensation but are not specifically documented as CMD1A triggers in the literature surveyed.
- **Age and sex act as major phenotype modifiers rather than independent causal risk factors:**
  - Age-dependent penetrance: onset typically third–fourth decade; penetrance exceeds 90–95% by the seventh decade (GeneReviews, PMID:20301717).
  - **Sex differences:** Male *LMNA* carriers present with clinical manifestations at a younger age than females (42 vs. 54 years); women with *LMNA* DCM have ~45% lower risk of life-threatening arrhythmia than men; male sex is one of the four independent risk factors for malignant ventricular arrhythmia in the van Rijsingen risk model (PMID:22281253).

### Protective Factors
- No specific human genetic or environmental protective factor against CMD1A has been established in the literature surveyed. In animal/cellular models, creatine and L-carnitine supplementation attenuated muscular laminopathy phenotypes in *LMNA*-mutant transgenic zebrafish (*Sci Rep* 2024, PMC11150447) — a MODEL_ORGANISM-level signal only, not yet translated to human protective evidence.
- Female sex functions as a partial phenotype-attenuating (not preventive) factor, as above.

### Gene-Environment Interactions
No specific documented gene-environment interaction studies for *LMNA* cardiomyopathy were identified in this search; this is a data gap relative to more common DCM etiologies.

---

## 3. Phenotypes

### Cardiac electrical phenotypes (typically first to manifest)
- **Conduction system disease** — sinus node dysfunction/sinus bradycardia, progressive atrioventricular (AV) block (first-degree through complete heart block), almost always precedes or co-occurs with structural DCM. Suggested term: **HP:0006682** (Abnormal atrioventricular conduction) / **HP:0001513** progressing through degrees of AV block; **HP:0001677** (Coronary artery atherosclerosis – not relevant) — more precisely **HP:0011711** (First degree atrioventricular block) or general **HP:0005180** (Sinoatrial block)/**HP:0001696** (Third degree atrioventricular block).
- **Atrial fibrillation / atrial flutter / supraventricular tachycardia** — HP:0005110 (Atrial fibrillation), HP:0004308 (Ventricular arrhythmia, more broadly).
- **Ventricular tachyarrhythmia / ventricular fibrillation** — HP:0004756 (Ventricular fibrillation), HP:0001696-type terms; malignant VT/VF is the proximate mechanism of sudden death.
- **Sudden cardiac death** — HP:0001645 (Sudden death) — may be the presenting/only manifestation, occasionally with preserved or minimally reduced LVEF.

### Structural/functional cardiac phenotypes
- **Left ventricular dilation** — HP:0001635 (Congestive heart failure) / HP:0001644 (Dilated cardiomyopathy).
- **Reduced left ventricular ejection fraction / systolic dysfunction** — HP:0001635, HP:0001681 (Reduced left ventricular ejection fraction... general HP terms for cardiac dysfunction).
- **Left ventricular mural thrombus with systemic embolism** (a distinctive presenting feature) — related to HP:0004943 (Thromboembolism).
- **Heart failure symptoms** (dyspnea, fatigue, edema) — HP:0002094 (Dyspnea), HP:0003326 (Myalgia — not relevant), general heart-failure terms.

### Extracardiac/skeletal muscle phenotypes (variable, overlapping laminopathy spectrum)
- **Skeletal myopathy with humeroperoneal weakness and early joint contractures** in the Emery-Dreifuss muscular dystrophy (EDMD)-overlap phenotype — HP:0003693 (Distal muscle weakness), HP:0034880/HP:0002828 (Joint contractures).
- **Limb-girdle pattern proximal weakness** in the LGMD1B-overlap phenotype — HP:0003701 (Proximal muscle weakness).
- **Minimal-to-no skeletal involvement** is also a recognized presentation of the same causal variants — importantly, "the same *LMNA* mutations can cause any of these or overlapping phenotypes even within the same family," underscoring marked intrafamilial phenotypic heterogeneity (Disease Models & Mechanisms 2011, PMC3180218).

### Phenotype characteristics
- **Onset:** Typically third to fourth decade (adult onset); pediatric-onset cases occur but are less common than in TTN- or other sarcomeric DCM.
- **Severity/progression:** Progressive — conduction disease precedes overt LV dysfunction by a median of ~7 years (in a cohort of 64 individuals). Of 122 patients with preserved LV function at initial presentation, ~24% developed new LV dysfunction and ~7% developed overt heart failure over 7 years (GeneReviews, PMID:20301717).
- **Frequency (population-level, among LMNA carriers):** Penetrance is age-dependent, reaching >90–95% by the 7th decade; ~90% of carriers >30 years old with cardiac manifestations are considered high-risk for arrhythmic sudden death.
- **Imaging phenotype (cardiac MRI):** 88% of asymptomatic/mildly symptomatic carriers show typical myocardial fibrosis on late gadolinium enhancement (LGE), predominantly mid-myocardial in the basal septum; 73% show a nonischemic midmyocardial/subepicardial LGE pattern; ~15% show an atypical "pseudo-infarct" transmural LGE pattern involving apical/free-wall segments (Steckman et al./various CMR series; *JACC Cardiovasc Imaging* and *J Cardiovasc Magn Reson* 2011, PMC/Springer link). A 2025 study found that variant-specific LGE patterns influence clinical outcomes (PMID:40689545).

### Quality of life impact
Not separately quantified in disease-specific EQ-5D/SF-36 studies in the sources surveyed; QoL burden is inferred from the combined burden of early heart failure, ICD/pacemaker implantation, arrhythmia symptoms, and (in overlap phenotypes) progressive skeletal myopathy affecting mobility and activities of daily living. This is a data gap for CMD1A specifically.

---

## 4. Genetic/Molecular Information

### Causal Gene
- **LMNA** (lamin A/C), HGNC:6636, chromosome 1q22, NCBI Gene ID 4000. Encodes prelamin A and lamin C via alternative splicing of a single transcript; prelamin A undergoes post-translational farnesylation/proteolytic maturation to mature lamin A.
- Protein: UniProt P02545 (Prelamin-A/C).

### Pathogenic Variants
- **Variant spectrum:** >450 disease-associated variants across all *LMNA*-associated diseases; cardiac disease arises from missense mutations (predominantly in the central α-helical rod domain, per the original Fatkin et al. 1999 description), as well as nonsense, frameshift, small indel, and splice-site variants distributed throughout the gene. No single genotype-phenotype correlation has been firmly established for CMD1A specifically (GeneReviews, PMID:20301717), though variant class (missense vs. non-missense/truncating/splice) associates with differential arrhythmic risk (see §2).
- **Variant classification/detection:** ACMG/AMP framework via ClinVar; sequence analysis (panel/exome/genome) detects >99% of pathogenic variants, gene-targeted deletion/duplication analysis <1% (GeneReviews).
- **Population frequency:** As with most dominant cardiomyopathy genes, pathogenic *LMNA* variants are rare/absent in gnomAD population reference panels; benign missense polymorphism background exists but pathogenic variants are private/family-specific in most cases.
- **Origin:** Predominantly germline; de novo rate is not well quantified ("unknown," per GeneReviews).
- **Functional consequence:** Predominantly **dominant-negative** — patients are heterozygous, producing both normal and mutant lamin A/C protein that co-assembles into a functionally compromised nuclear lamina meshwork; **haploinsufficiency** also contributes for truncating/nonsense-mediated-decay-prone alleles (a 2020 *Circ Genom Precis Med* study described an LMNA missense mutation causing nonsense-mediated mRNA decay and severe DCM, PMID referenced via AHA journals). This maps to `functional_impact_category: DOMINANT_NEGATIVE` (for most missense) or `PARTIAL_LOSS_OF_FUNCTION`/haploinsufficiency (for truncating/NMD-triggering variants).

### Modifier Genes
- **TTN (titin)** — co-occurring truncating variants worsen severity/hasten transplantation age in digenic *LMNA*/*TTN* carriers (PMID:23463027).
- **TMPO/LAP2** p.Arg690Cys polymorphism — modifies nuclear morphology phenotype severity (PMC9656322).

### Epigenetic Information
- Lamin A/C mutations disrupt **lamina-associated domains (LADs)** and heterochromatin organization at the nuclear periphery; integrated multi-omic analysis shows *LMNA* mutation-associated DCM features altered euchromatin/heterochromatin interactions with the lamina, driving downstream gene expression changes ("Integrated analysis reveals the alterations that LMNA interacts with euchromatin in LMNA mutation-associated dilated cardiomyopathy," PMC7788725). Mutant lamins also cause dislocation of heterochromatin and activation of Smad signaling in the H222P mouse model.

### Chromosomal Abnormalities
Not a chromosomal-abnormality-driven disease; CMD1A is caused by single-gene sequence-level variants in *LMNA*, not large structural rearrangements (contrast with syndromic laminopathies where large deletions can occur).

---

## 5. Environmental Information

- **Environmental factors:** No specific toxin, radiation, pollutant, or occupational exposure has been documented as causal or disease-modifying for CMD1A in the literature surveyed. This differs from acquired/toxin-mediated DCM etiologies (e.g., anthracycline cardiotoxicity), which are mechanistically distinct.
- **Lifestyle factors:** Standard heart-failure lifestyle counseling (avoidance of excess alcohol, standard cardiovascular risk-factor management) is presumably applied clinically but is not disease-specific in the sources reviewed.
- **Infectious agents:** None identified as causal; CMD1A is not an infectious or postinfectious cardiomyopathy.

---

## 6. Mechanism / Pathophysiology

CMD1A pathophysiology synthesizes across at least four convergent, non-mutually-exclusive mechanistic themes, drawn from iPSC-cardiomyocyte, mouse (H222P knock-in), and zebrafish model systems plus human myocardial specimen studies:

### a) Mechanical/structural nuclear fragility → nuclear envelope rupture
Mutant lamin A/C impairs lamin filament assembly at the inner nuclear membrane, producing **mechanically fragile nuclei** prone to rupture under the repetitive contractile mechanical stress of cardiomyocytes. iPSC-cardiomyocyte models show nuclear blebbing, impaired lamin localization to the nuclear envelope, and — under field electrical stimulation mimicking the native cardiac mechanical environment — increased nuclear senescence and apoptosis (PMC10846625, Mol Biol Cell 2023; PMID:37585285). A 2024 study identified **microtubule-generated forces** as a driver of this nuclear damage (*Nat Cardiovasc Res* 2024, PMC11212868). Nuclear envelope rupture in cardiomyocytes triggers early transcriptomic changes and **innate immune activation**, reversible by disrupting the LINC complex (nuclear-cytoskeletal coupling) — implicating cGAS-STING-adjacent DNA-damage/innate-immune sensing pathways, though one mouse study found pervasive nuclear ruptures preceded ECM signaling and disease onset *without* activating cGAS-STING (PMC10491116, 2023). A newer (2026) preprint reports that nuclear rupture causes global transcriptional deficiency via **loss of RNA polymerase II** from ruptured nuclei, downregulating genes essential for cardiomyocyte structure/function (bioRxiv 2026.04.03.716433).

### b) Chromatin/gene-expression dysregulation
Disruption of lamin-associated domains alters heterochromatin organization and gene expression programs relevant to cardiac muscle structure and function (PMC7788725).

### c) Signaling pathway activation
- **p38α MAPK pathway activation** downstream of nuclear envelope dysfunction is a well-established driver of cardiomyocyte dysfunction and was the basis for a targeted therapeutic (ARRY-371797, see §12).
- **PDGF pathway (PDGFRβ) activation** contributes to LMNA-DCM pathogenesis, nominating PDGFRβ inhibition (e.g., imatinib) as a candidate therapeutic target (*Nat Rev Cardiol* 2019 commentary on this pathway; original mechanistic work cited via OMIM/PMID search).
- **ERK1/2-related signaling** and **mTOR/MAPK pathway hyperactivation** — genome-wide transcriptome analysis of Lmna H222P mouse hearts showed abnormal increases in both MAPK and mTOR pathway activity.
- **Smad signaling activation** accompanies fibrosis and heterochromatin dislocation in the H222P mouse model.
- **Cardiac sodium channel (SCN5A-related) dysfunction** has been reported in an EDMD patient with an *LMNA* mutation, linking nuclear lamina disruption to ion-channel dysfunction relevant to conduction disease (Frontiers Cardiovasc Med 2022).

### d) Mitochondrial dysfunction and oxidative stress
- Mutant lamin A/C interacts with and accelerates degradation of **SIRT1**, driving mitochondrial dysfunction and oxidative stress.
- Lamin A/C deficiency-mediated **ROS elevation** contributes to pathogenic iPSC-model phenotypes (*Nat Commun* 2024, PMID reference via Nature.com).
- The p.H222P mutation impairs **mitochondrial calcium uptake**, contributing to heart failure in a human cardiac laminopathy model (bioRxiv 2024).

### e) Extracellular matrix remodeling / fibrosis
The mutant p.H222P lamin A protein drives **LOXL2-mediated extracellular matrix remodeling** in both patient-derived cardiomyocytes and mouse models (bioRxiv 2025), consistent with the mid-myocardial fibrosis seen on cardiac MRI in human carriers.

### Causal chain summary
**Germline *LMNA* variant → dominant-negative/haploinsufficient nuclear lamina assembly defect → mechanically fragile cardiomyocyte nuclei → nuclear envelope rupture, DNA damage, chromatin/LAD disorganization → dysregulated gene expression + p38 MAPK/PDGFRβ/mTOR-ERK signaling activation + mitochondrial dysfunction (SIRT1 loss, impaired Ca²⁺ uptake, ROS) → cardiomyocyte apoptosis/senescence, conduction-system tissue dysfunction, and myocardial fibrosis (LOXL2-driven ECM remodeling) → progressive conduction disease, arrhythmia, and dilated cardiomyopathy → heart failure and/or sudden arrhythmic death.**

Upstream nodes: the primary genetic lesion and its effect on lamina assembly. Midstream: nuclear rupture, chromatin dysregulation, signaling activation, mitochondrial dysfunction. Downstream: cardiomyocyte death/dysfunction, conduction tissue disease, fibrosis, clinical arrhythmia/DCM/SCD.

### Cell types and biological processes involved
- **Cell types (CL):** cardiac muscle cell / cardiomyocyte (CL:0000746), cardiac conduction system cells (e.g., sinoatrial/AV nodal cells), cardiac fibroblast (CL:0002548) (ECM remodeling arm), skeletal myocyte (CL:0000188) in overlap phenotypes.
- **Suggested GO biological processes:** nuclear envelope organization (GO:0006998), chromatin organization (GO:0006325), positive regulation of stress-activated MAPK cascade (GO:0032874), platelet-derived growth factor receptor signaling pathway (GO:0048008), regulation of mitochondrial calcium ion concentration, response to oxidative stress (GO:0006979), extracellular matrix organization (GO:0030198), regulation of cardiac conduction (GO:0010468/GO:1901844), cellular senescence (GO:0090398), intrinsic apoptotic signaling pathway (GO:0097193).
- **Subcellular/GO Cellular Component:** nuclear envelope (GO:0005635), nuclear lamina (GO:0005652), nucleoplasm; mitochondrion (GO:0005739) for the SIRT1/Ca²⁺-uptake arm.

### Molecular profiling (omics)
- **Transcriptomics:** Genome-wide expression changes in Lmna H222P mouse hearts implicate MAPK/mTOR pathway genes; single-nucleus/bulk transcriptomic studies of nuclear-ruptured cardiomyocytes show global transcriptional deficiency and immune-gene induction (bioRxiv 2024/2026 studies above).
- **Proteomics/mechanistic profiling:** iPSC-CM studies characterize nuclear lamina protein mislocalization.
- **Single-cell/advanced technologies:** iPSC-cardiomyocyte single-cell nuclear morphology and apoptosis/senescence assays under electrical pacing stress are the primary "advanced technology" readout used in this disease to date; no large-scale human single-cell/spatial transcriptomic atlas specific to CMD1A myocardium was identified in this search (data gap).

---

## 7. Anatomical Structures Affected

- **Primary organ:** Heart — specifically left ventricular myocardium (dilation, systolic dysfunction) and the **cardiac conduction system** (sinoatrial node, atrioventricular node, His-Purkinje system) — UBERON:0000948 (heart), UBERON:0002080 (heart left ventricle), UBERON:0002382 (conducting system of the heart, if a precise term is available; else UBERON:0006630 atrioventricular node/UBERON:0006631 sinoatrial node).
- **Secondary/complication organs:** Systemic circulation (embolic complications from LV mural thrombus), and — in EDMD/LGMD-overlap phenotypes — **skeletal muscle** (humeroperoneal or limb-girdle distribution) — UBERON:0001630 (skeletal muscle tissue), UBERON:0007829 (upper limb musculature) as relevant.
- **Body systems involved:** Cardiovascular system (primary); musculoskeletal system (secondary, in overlap phenotypes).
- **Tissue/cell level:** Cardiac muscle tissue (myocardium), conduction-system nodal/junctional tissue, cardiac interstitium/fibroblasts (fibrosis).
- **Subcellular level (GO Cellular Component):** Nuclear envelope/nuclear lamina (primary site of protein localization and dysfunction), mitochondria (secondary, functional dysfunction site).
- **Localization/laterality:** Bilateral/global cardiac chamber involvement (not typically lateralized); myocardial fibrosis characteristically localizes to the **mid-myocardial basal septum**, with a subset showing atypical apical/free-wall transmural "pseudo-infarct" patterns.

---

## 8. Temporal Development

- **Onset:** Typically early-to-mid adulthood (third to fourth decade); congenital/pediatric-onset presentations occur but are less characteristic than in some other genetic DCMs. Onset pattern is **insidious** electrically (subclinical conduction abnormalities detectable on ECG years before structural disease) with the possibility of an **acute** first presentation as sudden cardiac death.
- **Progression:**
  - Sequential pattern: conduction system disease (sinus/AV node dysfunction) → atrial arrhythmias → ventricular arrhythmias/dysfunction → LV dilation/systolic dysfunction → heart failure.
  - Median lag from ECG abnormality to detectable LV dysfunction: ~7 years.
  - Of patients with preserved LV function at baseline, ~24% develop new LV dysfunction and ~7% develop heart failure within 7 years.
  - Disease course is **progressive** and generally does not remit; no spontaneous remission pattern is described.
- **Stages:** Not formally staged with a named clinical staging system (unlike, e.g., cancer), but clinically conceptualized as: (1) asymptomatic genotype-positive/ECG-abnormal stage, (2) conduction disease/arrhythmia stage with preserved EF, (3) overt DCM/heart failure stage, (4) end-stage requiring transplant/mechanical support.
- **Critical periods:** The window when conduction disease is present but LV function is preserved is clinically critical for arrhythmic risk stratification and pre-emptive ICD decision-making (before EF falls below 35%), since SCD can occur even with preserved systolic function.

---

## 9. Inheritance and Population

### Epidemiology
- **Prevalence among LMNA carriers:** By definition, this is a fully penetrant-trending Mendelian disease among variant carriers (>90–95% by age 70).
- **Contribution to DCM overall:**
  - *LMNA* pathogenic variants account for **~5–13% of idiopathic/nonsyndromic DCM** cases (GeneReviews).
  - Approximately **5–10% of familial DCM** and **2–5% of sporadic DCM** cases (multiple concordant sources).
  - Up to **33% of DCM cases specifically associated with atrioventricular conduction disease**, and **40–50% of inherited DCM with accompanying conduction disease**.
  - LMNA is, after **TTN**, the **second most common single-gene cause of nonsyndromic DCM**.
  - Some series report *LMNA* variants in up to ~8% of all DCM patients broadly.
  - Background: overall DCM prevalence is estimated at ~1 in 2,500 individuals; inherited/familial forms account for 30–50% of DCM overall.

### Inheritance Pattern
- **Autosomal dominant.**
- **Penetrance:** Age-dependent and incomplete at younger ages but near-complete (>90–95%) by the seventh decade; described in one large multicenter cohort as "young onset, high penetrance" (*Eur Heart J* 2018, DOI 10.1093/eurheartj/ehx818, https://academic.oup.com/eurheartj/article/39/10/853/4583488) — this study also reported frequent need for heart transplantation.
- **Expressivity:** Highly variable, including intrafamilial variability — the same variant can produce isolated cardiac disease, EDMD, or LGMD1B phenotypes even within one family, implicating modifier genes/environment.
- **De novo rate:** Not well quantified ("unknown" per GeneReviews); most cases appear familial once ascertained.
- **Founder effects, consanguinity, germline mosaicism, carrier frequency:** Not specifically documented for CMD1A in the sources reviewed (data gap) — contrast with autosomal recessive laminopathies (e.g., some CMD/EDMD-AR forms) where consanguinity is more relevant.

### Population Demographics
- **Sex ratio / distribution:** No strong sex-skew in prevalence, but pronounced sex-based phenotype differences: males present earlier (mean 42 vs. 54 years) and carry ~higher arrhythmic risk (male sex is one of four independent risk factors for malignant ventricular arrhythmia); women have a more favorable overall long-term prognosis in DCM broadly, consistent with LMNA-specific data.
- **Geographic distribution:** No specific endemic/founder population identified in this search; described cohorts span European (Netherlands/France/Italy-led consortium studies) and other populations without strong geographic clustering reported.
- **Age distribution:** Concentrated in the 20s–50s at diagnosis, consistent with the age-dependent penetrance curve above.

---

## 10. Diagnostics

### Clinical/Laboratory Tests
- **ECG:** First-line and often earliest abnormal test — detects sinus bradycardia, PR prolongation, AV block, atrial arrhythmias.
- **24–48 hour ambulatory rhythm monitoring:** Recommended annually in gene-positive/ECG-abnormal individuals per GeneReviews management guidance.
- **Echocardiography:** LV chamber size/systolic function assessment; part of both diagnostic workup and annual/biennial surveillance.
- **Cardiac MRI with late gadolinium enhancement (LGE):** Highly informative — detects mid-myocardial basal septal fibrosis in the large majority of carriers (88% in one series) even when asymptomatic; LGE pattern (typical midmyocardial/subepicardial [73%] vs. atypical transmural "pseudo-infarct" pattern [~15%]) is prognostically relevant and variant-specific outcome associations have been reported (PMID:40689545, 2025).
- **Electrophysiology study:** May be used in select cases for arrhythmia risk characterization.
- **Endomyocardial biopsy/histopathology:** Not routine; when performed, may show nonspecific fibrosis, occasionally lymphocytic infiltrate mimicking myocarditis, or idiopathic cardiomyopathic changes; myocardial specimens from digenic LMNA/TTN cases show increased nuclear length, sarcomeric disorganization, myonuclear clustering.

### Genetic Testing
- **Recommended approach:** A comprehensive cardiomyopathy multigene panel or exome/genome sequencing, rather than *LMNA* single-gene testing alone, given phenotypic and genetic overlap with other DCM/arrhythmia genes.
- **Sequence analysis** detects >99% of pathogenic *LMNA* variants; **deletion/duplication (CNV) analysis** identifies the remaining <1%.
- **Cascade/family testing:** Once a familial variant is identified, targeted single-variant testing is used for at-risk relatives, supporting prenatal and preimplantation genetic testing where desired.
- **GTR entry:** "Laminopathy testing (LMNA)" clinical genetic test listed in NCBI GTR (https://www.ncbi.nlm.nih.gov/gtr/tests/237259/).

### Clinical Criteria and Differential Diagnosis
No disease-specific formal diagnostic criteria system (e.g., no "CMD1A Duke criteria" equivalent) beyond standard DCM diagnostic criteria (LV dilation + reduced EF) plus a confirmed pathogenic *LMNA* variant. **Differential diagnosis** should encompass the full nonsyndromic DCM gene set, with particular attention to other arrhythmia/conduction-disease-associated cardiomyopathy genes (e.g., *SCN5A*, *FLNC*, *DES*, *RBM20*, *PLN*) and to:
- Arrhythmogenic right ventricular cardiomyopathy/arrhythmogenic cardiomyopathy
- *DES* (desmin)-related myopathy
- Limb-girdle muscular dystrophy (non-LMNA forms)
- Emery-Dreifuss muscular dystrophy (non-LMNA forms, e.g., *EMD*/emerin-related X-linked EDMD1)

### Screening
Cascade genetic screening of first-degree relatives is the primary screening modality once a proband's pathogenic variant is identified; there is no population-wide newborn or carrier screening program for *LMNA* cardiomyopathy specifically.

---

## 11. Outcome/Prognosis

### Survival and Mortality
- LMNA cardiomyopathy is characterized in the literature as showing **"young onset, high penetrance, and frequent need for heart transplantation"** (*Eur Heart J* 2018, https://academic.oup.com/eurheartj/article/39/10/853/4583488).
- **~90% of carriers older than 30 years with cardiac manifestations are considered high-risk for sudden arrhythmic death.**
- Digenic *LMNA*/*TTN* carriers require heart transplantation at a significantly younger age than *LMNA*-only carriers (PMID:23463027).

### Morbidity/Complications
- Progressive heart failure, need for pacemaker/ICD implantation, atrial fibrillation with thromboembolic risk (including LV mural thrombus with systemic embolism as a presenting feature), progressive skeletal myopathy in overlap phenotypes.

### Prognostic Factors / Risk Stratification
The **van Rijsingen risk model** (2012, PMID:22281253; 269 LMNA carriers, multicenter European cohort) identified **four independent risk factors for malignant ventricular arrhythmia**:
1. Non-sustained ventricular tachycardia (NSVT)
2. LVEF <45% at first clinical contact
3. Male sex
4. Non-missense mutation type (insertion/deletion, truncating, or splice-affecting)

> "Nonsustained VT, LVEF <45% at the first clinical contact, male sex, and non-missense mutations (ins-del/truncating or mutations affecting splicing)" are independent risk factors for malignant ventricular arrhythmias in LMNA carriers. (van Rijsingen et al. 2012, *JACC* 59:493-500, PMID:22281253)

This was formalized into the **"LMNA-risk VTA" (LMNA-risk ventricular tachyarrhythmia) calculator** (Wahbi et al.), which has since been **externally validated** for timing cardioverter-defibrillator implantation, though validation studies report the calculator's specificity is low (~26%) and it tends to overestimate arrhythmic risk, particularly in male patients — the proposed ≥7% predicted 5-year risk threshold may be too low for primary-prevention ICD selection (Heart Rhythm 2022/2023, PMID referenced via ScienceDirect S1547527122026868).

### Quality of Life
Not separately quantified with disease-specific instruments in the sources reviewed (data gap), though QoL is presumed reduced by early device therapy, arrhythmia burden, and progressive heart failure/myopathy.

---

## 12. Treatment

### Pharmacotherapy (Guideline-Directed Medical Therapy for Heart Failure)
Standard heart-failure regimen, applied as in other DCM etiologies:
- **Beta-blockers** — NCIT:C15986 (Pharmacotherapy) treatment_term; caution: beta-blockers, calcium channel blockers, and other AV-node-suppressing agents should be **avoided/used cautiously** in patients without a pacemaker/ICD in place, given the conduction-disease substrate.
- **ACE inhibitors / angiotensin receptor blockers**
- **Aldosterone antagonists (mineralocorticoid receptor antagonists)**
- **Diuretics**
- **Sacubitril/valsartan (ARNI)** — reported as considerable/used in case reports as part of GDMT, though real-world uptake is inconsistent.
- Note: "in limited studies, the efficacy of even maximal guideline-directed medical therapy has been suboptimal in LMNA-related DCM, revealing an unmet clinical need" (*J Cardiac Failure* 2023 review, S1071-9164(23)00313-5).

### Device Therapy (Disease-Defining Intervention)
- **Implantable cardioverter-defibrillator (ICD):** Central to management given the disproportionate SCD risk relative to degree of LV dysfunction. 2023 ESC Cardiomyopathy Guidelines recommend ICD in LMNA-variant carriers with EF >35% as **Class 2a (with risk factors present)** or **Class 2b (no risk factors)**; ICD implantation should be considered **before EF falls below 35%** given established or anticipated arrhythmia risk — this is a gene-specific deviation from standard EF-only ICD criteria used in non-genetic DCM.
- **Permanent pacemaker:** For symptomatic bradyarrhythmia/high-degree AV block — though ICD is generally favored over pacemaker-only given concurrent SCD risk.
- **Anticoagulation** for atrial fibrillation/flutter or LV mural thrombus.

### Advanced/Surgical Therapy
- **Cardiac transplantation** and **mechanical circulatory support** for refractory heart failure — needed frequently and at young age in this population (as above).

### Investigational/Targeted Therapeutics
- **ARRY-371797 (PF-07265803)**, a **p38 MAPK inhibitor**, was developed specifically for LMNA-DCM based on the p38α MAPK activation mechanism:
  - **Phase 2 study** showed improved 6-minute walk test (6MWT) distance at 12 weeks, preserved through 144 weeks (PMID referenced via AHA Circ Genom Precis Med journal).
  - **REALM-DCM Phase 3 trial** (multinational, randomized, placebo-controlled; NYHA II/III, LVEF ≤50%, ICD-implanted patients; primary endpoint change in 6MWT at week 24) — **result: futility, without safety concerns** (*Circ Heart Fail* 2024, PMID:38979608). This represents the highest-profile completed disease-specific drug trial for CMD1A and its negative Phase 3 result underscores the continued unmet therapeutic need.
- **PDGFRβ inhibition (e.g., imatinib):** Proposed as a novel therapeutic target based on PDGF pathway activation in LMNA-DCM pathogenesis (*Nat Rev Cardiol* 2019 commentary); imatinib has shown anti-fibrotic efficacy in a general isoproterenol-induced cardiac fibrosis mouse model (PMC5453565) by blocking PDGFR phosphorylation, but disease-specific LMNA-DCM in vivo efficacy data were not identified in this search (extrapolated target, not yet clinically tested in CMD1A specifically).
- **Gene-based/RNA-targeted approaches (preclinical/conceptual stage):**
  - **AAV-mediated gene therapy/gene supplementation** — under general exploration for genetic cardiomyopathies given AAV's robust cardiac tropism.
  - **Antisense oligonucleotide (ASO)-mediated exon skipping** — a clinically validated strategy in other cardiomyopathies (e.g., titin-based DCM, DMD) proposed as a conceptually transferable strategy for select LMNA variants amenable to exon skipping, though no LMNA-DCM-specific clinical program was identified in this search.
  - **CRISPR/Cas9 gene editing** — theoretically feasible for correcting *LMNA* variants via homology-directed repair; remains preclinical.
  - A comprehensive review, "LMNA-related cardiomyopathy: From molecular pathology to cardiac gene therapy" (PMC12627347, 2025), surveys this translational landscape.
- **Nutraceutical/metabolic modifiers (model-organism evidence only):** Creatine and L-carnitine attenuated muscular laminopathy phenotypes in *LMNA*-mutant transgenic zebrafish via AMPK/mTOR pathway modulation (*Sci Rep* 2024, PMC11150447) — MODEL_ORGANISM evidence, not yet human-tested for CMD1A.

### Treatment Outcomes/Strategy
- No LMNA-DCM-specific combination or genotype-guided precision treatment algorithm currently exists beyond gene-informed ICD-timing risk models (§11); treatment remains guideline-directed HF therapy plus early/aggressive device therapy, given the demonstrated inadequacy of medical therapy alone and the failure of the targeted p38 MAPK inhibitor in Phase 3.

**Suggested NCIT terms:** NCIT:C15986 (Pharmacotherapy), NCIT:C15747 (Supportive Care), NCIT:C15329 (Surgical Procedure — for transplantation/device implantation broadly), device-related codes for ICD/pacemaker (no precise NCIT clinical-action code identified; DEVICE modality per dismech convention), NCIT:C15289 (Organ Transplantation) for cardiac transplant.

---

## 13. Prevention

### Levels of Prevention
- **Primary prevention:** Not applicable in the traditional sense (no modifiable exposure prevents the underlying genetic disease); the closest analog is **genetic counseling and reproductive options** (prenatal diagnosis, preimplantation genetic testing) once a familial variant is identified, to prevent transmission.
- **Secondary prevention (early detection):** Cascade genetic testing plus **regular cardiovascular surveillance** in asymptomatic carriers is the primary secondary-prevention strategy:
  - Every 1–2 years: history, physical exam, echocardiogram, ECG in asymptomatic gene carriers.
  - Annual (at minimum): ECG, 24–48 hour rhythm monitoring, LV function assessment once ECG abnormalities are present.
  - Immediate evaluation triggered by any new cardiac symptom.
- **Tertiary prevention:** Early ICD implantation **before** EF drops below 35% specifically to preempt SCD as the first/fatal event — this is the disease's signature tertiary-prevention intervention, reflecting that arrhythmic risk in LMNA carriers is disproportionate to degree of systolic dysfunction.

### Genetic Counseling
Formal genetic counseling is a core component of management given autosomal dominant inheritance, age-dependent penetrance, and variable expressivity (including possible skeletal myopathy overlap). Family members should be offered variant-specific testing; asymptomatic carriers require ongoing surveillance rather than reassurance, given the incompletely penetrant-at-young-age but eventually high-penetrance natural history.

### Public Health / Population Screening
No public health, vaccination, or population-level screening program applies (not infectious, no newborn screening program identified in this search).

### Prophylaxis
- **Anticoagulation** in patients with atrial fibrillation or documented LV thrombus, to prevent thromboembolic stroke/systemic embolism.
- **Avoidance of AV-node-suppressing drugs** (beta-blockers, calcium channel blockers) in carriers without device protection, to avoid precipitating symptomatic bradyarrhythmia/heart block.

---

## 14. Other Species / Natural Disease

- **Taxonomy:** No robust literature on spontaneously occurring, naturally arising LMNA-cardiomyopathy in companion animals or wildlife was identified in this search (data gap; contrast with some other cardiomyopathies with veterinary natural-disease correlates, e.g., feline HCM). All animal data identified are **induced/engineered models** (see §15), not natural disease.
- **Orthologous gene:** Mouse *Lmna* (MGI:96794), zebrafish *lmna* — used to generate engineered models; no NCBI Gene ortholog-based natural-disease report found.

---

## 15. Model Organisms

### Mouse Models
- **Lmna H222P knock-in mouse (Lmna^H222P/H222P):** One of the first mouse models carrying a human-relevant missense mutation (originally identified in a family with autosomal dominant EDMD). Homozygous males show normal embryonic development but develop reduced locomotor activity, abnormal stiff gait, and die by 9 months. **Cardiac phenotype:** chamber dilation, hypokinesia, conduction defects. **Histopathology:** muscle degeneration with fibrosis, heterochromatin dislocation, activated Smad signaling in heart and skeletal muscle. **Transcriptomics:** dysregulated stress-activated MAPK and mTOR signaling with abnormally increased pathway activity in heart tissue (Arimura et al. 2005, *Hum Mol Genet*, PMID:15548545). This model is considered a good recapitulation of human striated-muscle laminopathy (RECAPITULATES-type relationship with the human "chamber dilation and conduction defect" mechanism nodes).
  - **Emerin (EMD) deficiency modifies the H222P phenotype differently in skeletal vs. cardiac muscle** in Lmna^H222P/H222P mice, indicating tissue-specific modifier effects (PMC6701770).
- **Cardiac-specific Lmna-mutant mice** used to study nuclear envelope rupture: pervasive nuclear envelope ruptures precede ECM/fibrotic signaling and overt disease onset, without cGAS-STING activation (PMC10491116, 2023) — a **FAILS_TO_RECAPITULATE**-type nuance relative to the innate-immune-activation mechanism seen in some other model systems, worth flagging as a HUMAN_MODEL_MISMATCH-relevant caveat if curated.
- **General Lmna-null/knockout mice** (Lmna⁻/⁻) — earlier-generation models with more severe, EDMD-like phenotype and early postnatal lethality (background literature, not detailed in this search but foundational to the field).

### Zebrafish Models
- **CRISPR/Cas9-generated *lmna*-knockout zebrafish:** larvae show decreased heart rate versus wild-type; used to characterize cardiac performance and electrophysiology via high-resolution imaging.
- **Heart-specific transgenic zebrafish expressing laminopathic mutations** (e.g., LMNA L35P, LMNA R453W): reduced swimming speed and muscle endurance; drug-response studies show **L-carnitine rescues muscle endurance in LMNA(L35P)** fish, and **creatine reverses muscle endurance in LMNA(R453W)** fish via AMPK/mTOR pathway activation (*Sci Rep* 2024, PMC11150447). A separate JACC-published zebrafish laminopathy study reported **early-onset cardiac conduction dysfunction** upon lamin A disruption (JACC 2020, S0735-1097(20)31330-9), directly recapitulating the human conduction-disease-first phenotype.

### Human iPSC-Derived Cardiomyocyte (iPSC-CM) Models
- Extensively used as the primary human-cell-based model system for CMD1A mechanism studies (IN_VITRO evidence source):
  - Patient-derived LMNA-mutant iPSC-CMs show nuclear morphology abnormalities (blebbing), slowed proliferation, increased cellular senescence, and increased apoptosis, all exacerbated under electrical field stimulation mimicking the cardiac mechanical/electrical environment (PMC8346174; PMC6627421).
  - Impaired lamin localization to the nuclear envelope and nuclear damage under mechanical/microtubule-generated forces (PMC10846625; *Nat Cardiovasc Res* 2025, PMC11212868).
  - **Limitation:** iPSC-CMs, despite showing DNA damage signatures, largely **lack overt nuclear ruptures** seen in mature adult cardiomyocytes/mouse models, likely due to an immature cytoskeleton/nucleoskeleton and rounder nuclear morphology — an explicit model-fidelity caveat (a HUMAN_MODEL_MISMATCH-relevant point: iPSC-CM immaturity limits translational fidelity for the nuclear-rupture arm specifically, even though it captures upstream DNA-damage/lamin-mislocalization phenotypes).
  - Lamin A/C-deficient iPSC-CM models show elevated ROS contributing to pathogenic DCM phenotypes (*Nat Commun* 2024).
  - The p.H222P mutation in human iPSC-CM-based laminopathy models shows impaired mitochondrial calcium uptake driving heart-failure-relevant phenotypes (bioRxiv 2024).

### Model Resources
MGI (Mouse Genome Informatics) for *Lmna* mouse alleles; ZFIN for zebrafish *lmna* models; standard iPSC repositories/Cellosaurus-type resources for patient-derived LMNA-mutant iPSC lines (specific line accessions not enumerated in this search).

---

## Summary Table: Key Evidence Citations

| Topic | Citation | PMID/DOI |
|---|---|---|
| Original disease description | Fatkin et al., NEJM 1999 | PMID:10580070 |
| Penetrance/transplant burden cohort | *Eur Heart J* 2018 | DOI:10.1093/eurheartj/ehx818 |
| Malignant VA risk factors (van Rijsingen model) | *JACC* 2012 | PMID:22281253 |
| Gene-based risk stratification | *Circ Cardiovasc Genet* 2017 | PMID:29237675 |
| Clinical management reference | GeneReviews (Hershberger & Jordan) | PMID:20301717 |
| Digenic LMNA/TTN modifier | *Eur J Hum Genet* 2013 | PMID:23463027 |
| ARRY-371797 Phase 2 | *Circ Genom Precis Med* | (AHA journals) |
| REALM-DCM Phase 3 (futility) | *Circ Heart Fail* 2024 | PMID:38979608 |
| H222P mouse model | Arimura et al., *Hum Mol Genet* 2005 | PMID:15548545 |
| LGE pattern and outcomes | 2025 *JAHA* study | PMID:40689545 |
| ESC 2023 Cardiomyopathy Guidelines | *Neth Heart J* summary | DOI:10.1007/s12471-025-01955-2 |

---

### Data Gaps Identified (for curator awareness)
1. No disease-specific quality-of-life instrument data (EQ-5D/SF-36) for CMD1A specifically.
2. No documented environmental/lifestyle risk-factor or gene-environment interaction studies specific to CMD1A.
3. De novo mutation rate, germline mosaicism, founder effects, and carrier frequency are not well quantified in the literature surveyed.
4. No natural (spontaneous) veterinary/wildlife disease model identified — only engineered mouse/zebrafish/iPSC systems.
5. PDGFRβ/imatinib and gene-therapy/ASO/CRISPR approaches remain preclinical/conceptual for this specific disease; no completed clinical trial data beyond the negative REALM-DCM p38 MAPK inhibitor trial.

---

**Sources:**
- [OMIM Entry #115200 — CARDIOMYOPATHY, DILATED, 1A; CMD1A](https://www.omim.org/entry/115200)
- [LMNA-Related Dilated Cardiomyopathy — GeneReviews®](https://www.ncbi.nlm.nih.gov/books/NBK1674/)
- [Orphanet: Familial dilated cardiomyopathy with conduction defect due to LMNA mutation](https://www.orpha.net/en/disease/detail/300751)
- [Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation — Eur Heart J](https://academic.oup.com/eurheartj/article/39/10/853/4583488)
- [Gene-Based Risk Stratification for Cardiac Disorders in LMNA Mutation Carriers — Circ Cardiovasc Genet](https://www.ahajournals.org/doi/10.1161/CIRCGENETICS.116.001603)
- [Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers — PubMed](https://pubmed.ncbi.nlm.nih.gov/22281253/)
- [Missense mutations in the rod domain of the lamin A/C gene — NEJM](https://www.nejm.org/doi/full/10.1056/NEJM199912023412302)
- [The Broad Spectrum of LMNA Cardiac Diseases — Frontiers in Physiology](https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00761/full)
- [The Pathogenic Mechanisms of and Novel Therapies for Lamin A/C-Related Dilated Cardiomyopathy — PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11357512/)
- [Mechanisms of allelic and clinical heterogeneity of lamin A/C phenotypes — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6335092/)
- [LMNA cardiomyopathy: cell biology and genetics meet clinical medicine — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3180218/)
- [Risk stratification in laminopathies and Emery Dreifuss muscular dystrophy — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5937217/)
- [Timing of cardioverter-defibrillator implantation — external validation of LMNA-risk VTA calculator — Heart Rhythm](https://www.heartrhythmjournal.com/article/S1547-5271(22)02686-8/fulltext)
- [High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN — MDPI Genes 2026](https://www.mdpi.com/2073-4425/17/4/370)
- [2023 ESC guidelines on the management of cardiomyopathies — Neth Heart J](https://link.springer.com/article/10.1007/s12471-025-01955-2)
- [Mouse model carrying H222P-Lmna mutation — Hum Mol Genet](https://academic.oup.com/hmg/article/14/1/155/2355798)
- [The Mutated p.H222P A-type Lamins Drive Loxl2-Mediated ECM Remodeling — bioRxiv 2025](https://www.biorxiv.org/content/10.1101/2025.01.10.632312.full.pdf)
- [Deficiency of emerin contributes differently to pathogenesis of skeletal and cardiac muscles in LmnaH222P/H222P mice — PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701770/)
- [Recent advances in animal and human pluripotent stem cell modeling of cardiac laminopathy — Stem Cell Res Ther](https://stemcellres.biomedcentral.com/articles/10.1186/s13287-016-0401-5)
- [Nuclear damage in LMNA mutant iPSC-derived cardiomyocytes — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10846625/)
- [Microtubule forces drive nuclear damage in LMNA cardiomyopathy — Nat Cardiovasc Res](https://www.nature.com/articles/s44161-025-00727-w)
- [Nuclear envelope rupture in cardiomyocytes orchestrates early transcriptomic changes and immune activation in LMNA-DCM — bioRxiv 2024](https://www.biorxiv.org/content/10.1101/2024.06.11.598511.full.pdf)
- [Pervasive nuclear envelope ruptures precede ECM signaling and disease onset without activating cGAS-STING — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10491116/)
- [Lamin A/C deficiency-mediated ROS elevation contributes to pathogenic phenotypes of DCM in iPSC model — Nat Commun 2024](https://www.nature.com/articles/s41467-024-51318-5)
- [The p.H222P lamin A/C mutation induces heart failure via impaired mitochondrial calcium uptake — bioRxiv 2024](https://www.biorxiv.org/content/10.1101/2024.08.21.609073.full.pdf)
- [PDGF pathway in LMNA-related dilated cardiomyopathy — Nat Rev Cardiol](https://www.nature.com/articles/s41569-019-0246-6)
- [Imatinib attenuates cardiac fibrosis by inhibiting PDGFR activation — PLOS ONE](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0178619)
- [REALM-DCM: Phase 3 trial of ARRY-371797 — Circ Heart Fail](https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.123.011548)
- [Efficacy and Safety of ARRY-371797 in LMNA-Related DCM: Phase 2 Study](https://www.ovid.com/journals/cgpm/fulltext/10.1161/circgen.122.003730~efficacy-and-safety-of-arry-371797-in-lmna-related-dilated)
- [LMNA-related cardiomyopathy: From molecular pathology to cardiac gene therapy — PMC 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12627347/)
- [Creatine and l-carnitine attenuate muscular laminopathy in LMNA mutation transgenic zebrafish — Sci Rep 2024](https://www.nature.com/articles/s41598-024-63711-7)
- [Disruption of lamin A leads to early-onset cardiac conduction dysfunction in zebrafish models of laminopathy — JACC 2020](https://www.jacc.org/doi/full/10.1016/S0735-1097(20)31330-9)
- [Doubly heterozygous LMNA and TTN mutations — Eur J Hum Genet](https://www.nature.com/articles/ejhg201316)
- [Variant-Specific Late Gadolinium Enhancement Patterns Influence Clinical Outcomes in LMNA-Related Cardiomyopathy — JAHA 2025](https://www.ahajournals.org/doi/10.1161/JAHA.124.041230)
- [Late gadolinium enhanced CMR of lamin A/C gene mutation related DCM — J Cardiovasc Magn Reson](https://link.springer.com/article/10.1186/1532-429X-13-30)
- [Sex-Related Differences in Genetic Cardiomyopathies — JAHA](https://www.ahajournals.org/doi/10.1161/JAHA.121.024947)
- [LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician — J Cardiac Failure](https://onlinejcf.com/article/S1071-9164(23)00313-5/abstract)
- [Testing for LMNA Gene Mutations is 'Woefully Underutilized' — Medscape](https://www.medscape.com/viewarticle/testing-lmna-gene-mutations-woefully-underutilized-can-help-2025a1000inb)
- [Laminopathy testing (LMNA) — NCBI GTR](https://www.ncbi.nlm.nih.gov/gtr/tests/237259/)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 37 |
| Resolved | 36 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 1 |
| Quoted claims checked | 2 |
| Quoted claims found in source | 1 |
| Quoted claims **not** found in source | 1 |
| Quoted claims with nothing to check against | 1 |
| References weighed for topical relevance | 36 |
| On topic | 24 |
| Off topic | 0 |

### Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked *abstract only* below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

- `PMID:10580070` *(abstract only)*: "Missense mutations in the rod domain of the lamin A/C gene provide a genetic cause for dilated cardiomyopathy and conduction-system disease... this intermediate filament protein has an important role in cardiac conduction and contractility."
  - closest text in source: "Missense mutations in the rod domain of the lamin A/C gene provide a genetic cause for dilated cardiomyopathy and indicate that this intermediate filament protein has an important role in cardiac conduction and contractility."

### Quotes that could not be checked

There was no text to compare these against, so they are neither confirmed nor contradicted:

- `DOI:10.1093/eurheartj/ehx818`: "young onset, high penetrance"
  - Reference resolved but exposes no abstract or full text to search